On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population

The theory of the clonal origin of cancer states that a tumour arises from one cell that acquires mutation(s) leading to the malignant phenotype. It is the current belief that many of these mutations give a fitness advantage to the mutant population allowing it to expand, eventually leading to disease. However, mutations that lead to such a clonal expansion need not give a fitness advantage and may in fact be neutral—or almost neutral—with respect to fitness. Such mutant clones can be eliminated or expand stochastically, leading to a malignant phenotype (disease). Mutations in haematopoietic stem cells give rise to diseases such as chronic myeloid leukaemia (CML) and paroxysmal nocturnal haemoglobinuria (PNH). Although neutral drift often leads to clonal extinction, disease is still possible, and in this case, it has important implications both for the incidence of disease and for therapy, as it may be more difficult to eliminate neutral mutations with therapy. We illustrate the consequences of such dynamics, using CML and PNH as examples. These considerations have implications for many other tumours as well.

[1]  M. Kimura,et al.  DNA and the neutral theory. , 1986, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[2]  A. Risitano,et al.  Eculizumab treatment modifies the immune profile of PNH patients. , 2012, Immunobiology.

[3]  Jeremy M. Stark,et al.  Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. , 2012, Blood.

[4]  J Gilbert,et al.  Theoretical introduction , 2019, Gender Terrains in African Cinema.

[5]  A. W. F. Edwards,et al.  The statistical processes of evolutionary theory , 1963 .

[6]  Peter Guttorp,et al.  Evidence that hematopoiesis may be a stochastic process in vivo , 1996, Nature Medicine.

[7]  A. Strasser,et al.  Is tumor growth sustained by rare cancer stem cells or dominant clones? , 2008, Cancer research.

[8]  J. Birch Genes and cancer , 1999, Archives of disease in childhood.

[9]  M. Kimura,et al.  An introduction to population genetics theory , 1971 .

[10]  S. Marley,et al.  Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. , 2005, Clinical science.

[11]  P. Jagers,et al.  Branching Processes: Variation, Growth, and Extinction of Populations , 2005 .

[12]  A Traulsen,et al.  Progenitor cell self‐renewal and cyclic neutropenia , 2009, Cell proliferation.

[13]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[14]  Ken Kurokawa,et al.  Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). , 2006, Blood.

[15]  Arne Traulsen,et al.  Stochastic Dynamics of Hematopoietic Tumor Stem Cells , 2007, Cell cycle.

[16]  Marek Kimmel,et al.  Branching processes in biology , 2002 .

[17]  S M Lewis,et al.  Natural history of paroxysmal nocturnal hemoglobinuria. , 1995, The New England journal of medicine.

[18]  Jorge M Pacheco,et al.  Neutral evolution in paroxysmal nocturnal hemoglobinuria , 2008, Proceedings of the National Academy of Sciences.

[19]  G. Bell Fluctuating selection: the perpetual renewal of adaptation in variable environments , 2010, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  C. Verfaillie,et al.  A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. , 2001, Blood.

[21]  Lucio Luzzatto,et al.  Somatic Mutations in Paroxysmal Nocturnal Hemoglobinuria: A Blessing in Disguise? , 1997, Cell.

[22]  W. Ewens Mathematical Population Genetics , 1980 .

[23]  David A. Williams,et al.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. , 2012, Blood.

[24]  Jl Lewis,et al.  Discordant erythropoiesis in CML , 1998, Leukemia.

[25]  Lucio Luzzatto,et al.  The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). , 2006, Blood.

[26]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[27]  Y. Kanakura,et al.  Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria , 2012, British journal of haematology.

[28]  A. Traulsen,et al.  Evolutionary dynamics of chronic myeloid leukemia. , 2010, Genes & cancer.

[29]  P. Holgate,et al.  Branching Processes with Biological Applications , 1977 .

[30]  D. Alling,et al.  Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. , 1985, The Journal of clinical investigation.

[31]  Arne Traulsen,et al.  Somatic mutations and the hierarchy of hematopoiesis , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  Arne Traulsen,et al.  On the Origin of Multiple Mutant Clones in Paroxysmal Nocturnal Hemoglobinuria , 2007, Stem cells.

[33]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[34]  W. Ewens Mathematical Population Genetics : I. Theoretical Introduction , 2004 .

[35]  D. Tenen,et al.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. , 2010, Blood.

[36]  A. Traulsen,et al.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells , 2009, Haematologica.

[37]  S. Richards,et al.  The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab , 2009, Therapeutics and clinical risk management.

[38]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[39]  Arne Traulsen,et al.  Multiple mutant clones in blood rarely coexist. , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.

[40]  L. Luzzatto,et al.  Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria , 1994, The Lancet.

[41]  P. Moran,et al.  The statistical processes of evolutionary theory. , 1963 .

[42]  T. Antal,et al.  Fixation of Strategies for an Evolutionary Game in Finite Populations , 2005, Bulletin of mathematical biology.

[43]  Anirvan M. Sengupta,et al.  Mutation-selection networks of cancer initiation: tumor suppressor genes and chromosomal instability. , 2003, Journal of theoretical biology.

[44]  A. Traulsen,et al.  Reproductive fitness advantage of BCR-ABL expressing leukemia cells. , 2010, Cancer letters.

[45]  Jorge M. Pacheco,et al.  Allometric Scaling of the Active Hematopoietic Stem Cell Pool across Mammals , 2006, PloS one.

[46]  Benjamin D. Simons,et al.  Defining the mode of tumour growth by clonal analysis , 2012, Nature.

[47]  A. Traulsen,et al.  Fixation times in evolutionary games under weak selection , 2008, 0812.0851.

[48]  T. Brümmendorf,et al.  Dynamics of Resistance Development to Imatinib under Increasing Selection Pressure: A Combination of Mathematical Models and In Vitro Data , 2011, PloS one.

[49]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[50]  J. Rowley A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[51]  D. Waxman A compact result for the time-dependent probability of fixation at a neutral locus. , 2011, Journal of theoretical biology.

[52]  J. Dick,et al.  Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. , 1996, Blood.

[53]  M. Kimura Evolutionary Rate at the Molecular Level , 1968, Nature.

[54]  H. Deeg,et al.  New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. , 1998, Blood.

[55]  M Kimura,et al.  SOLUTION OF A PROCESS OF RANDOM GENETIC DRIFT WITH A CONTINUOUS MODEL. , 1955, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Lassen,et al.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein , 2010, Proceedings of the National Academy of Sciences.